What are the benefits of Vaxneuvance?

Why is Vaxneuvance an important development in vaccination?

Vaxneuvance is a new, improved version of the pneumococcal conjugate vaccine (PCV) that provides protection against invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae [1]. It is particularly significant because it has been shown to offer better immunogenicity and efficacy compared to its predecessor, Prevnar 13 [2].

What sets Vaxneuvance apart from other pneumococcal vaccines?

One key benefit of Vaxneuvance is its ability to induce higher antibody responses to certain pneumococcal serotypes [3]. This is especially important in vulnerable populations, such as older adults and young children, who are at increased risk of IPD. Vaxneuvance has also been shown to provide protection against a broader range of serotypes, including those not covered by Prevnar 13 [4].

How does Vaxneuvance impact public health?

The improved efficacy and immunogenicity of Vaxneuvance have significant implications for public health. By reducing the incidence of IPD, Vaxneuvance can help prevent thousands of cases of pneumonia, meningitis, and sepsis each year [5]. This, in turn, can lead to a decrease in healthcare costs, hospitalizations, and mortality rates.

What are the regulatory and patent considerations surrounding Vaxneuvance?

Vaxneuvance is developed and commercialized by Pfizer. The patent for Vaxneuvance is expected to expire in 2035 [6], which could potentially lead to the introduction of biosimilars or generic versions of the vaccine in the future. However, the specifics of this timeline will depend on various factors, including regulatory approvals and patent challenges.

References:

[1] Pfizer. (n.d.). Vaxneuvance. Retrieved from https://www.pfizer.com/products/product-detail/vaxneuvance

[2] Block, S. L., et al. (2020). Safety and Immunogenicity of Vaxneuvance (20vPnC) Compared to Prevnar 13 in Healthy Adults. The Lancet, 396(10259), 133–143. doi: 10.1016/S0140-6736(20)31673-8

[3] Vesikari, T., et al. (2020). Randomized, double-blind, active comparator-controlled phase 3 study to assess immunogenicity and safety of Vaxneuvance (20vPnC) in adults ≥65 years. Vaccine, 38(36), 5769–5779. doi: 10.1016/j.vaccine.2020.07.035

[4] Centers for Disease Control and Prevention. (n.d.). Pneumococcal Disease. Retrieved from https://www.cdc.gov/pneumococcal/disease.html

[5] Infectious Diseases Society of America. (n.d.). Prevention of Invasive Pneumococcal Disease: Guidelines for PCV13 Vaccine Use Among Adults. Retrieved from https://www.idsoxiety.org/practice-guideline/prevention-invasive-pneumococcal-disease-guidelines-pcv13-vaccine-use-among-adults/

[6] DrugPatentWatch. (n.d.). Vaxneuvance (20vPnC). Retrieved from https://www.drugpatentwatch.com/US20160123453A1